 Insmed Incorporated Nasdaq:INSM, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Food and Drug Administration FDA has granted breakthrough therapy designation for brensocatib formerly known as INS1007 for the treatment of adult patients with non-cystic fibrosis bronchiectasis NCFBE for reducing exacerbations. Brensocatib is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 DPP1 currently being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases. 